“Seventeen patients completed the RCT (randomized placebo-controlled crossover study). Cannabis was well tolerated, and had no pro- or antiparkinsonian action. There was no evidence for a treatment effect on levodopa-induced dyskinesia as assessed by the UPDRS [Unified Parkinson Disease Rating Scale], or any of the secondary outcome measures.

Conclusions: Orally administered cannabis extract resulted in no objective or subjective improvement in dyskinesias or parkinsonism.”